EXACT Sciences Corporation

390 articles with EXACT Sciences Corporation

• Exact Sciences And Mayo Clinic Initiate 150,000 Patient, 7-Year Study To Evaluate Real-World Impact Of Cologuard®

  10/14/2019

  Data from Prospective, Observational Study will Strengthen Clinical Evidence and Support Continued Cologuard Adoption

• Exact Sciences schedules third-quarter 2019 earnings call

  10/8/2019

  Exact Sciences Corp. announced that the company plans to release its third-quarter 2019 financial results after the close of the U.S. financial markets on Oct. 29, 2019.

• Cologuard® Gains FDA Approval For Use In Younger Americans, Ages 45 To 49

  9/23/2019

  Stool DNA test offers a sensitive, noninvasive, at-home option to screen for colorectal cancer, second deadliest cancer in U.S.

• Exact Sciences Named One of the 2019 Best Workplaces for Women by Great Place to Work® and FORTUNE

  9/19/2019

  Open jobs offer opportunity to join dynamic company

• Cologuard® Helps More People Get Screened In A Cost-Effective Way

  9/10/2019

  Exact Sciences announced that nearly 3 million people have been screened for colorectal cancer with Cologuard since FDA approval with half of those tested being previously unscreened.

• Exact Sciences to participate in September investor conference

  8/30/2019

  Exact Sciences Corp. (Nasdaq: EXAS) today announced that company management will be presenting at the following investor conference and invited investors to participate by webcast.

• Exact Sciences to participate in August investor conference

  8/2/2019

  Exact Sciences Corp. announced that company management will be presenting at the following investor conference and invited investors to participate by webcast.

• Second-quarter revenue increased 94 percent to $200 million and Cologuard test volume increased 93 percent to 415,000

  7/29/2019

  Exact Sciences Corp. announced that the company generated revenue of $199.9 million and screened approximately 415,000 people with Cologuard during the quarter ended June 30, 2019.

• Genomic (GHDX) Alert: Johnson Fistel Investigates Proposed Sale of Genomic Health, Inc.; Are Shareholders Getting a Fair Deal?

  7/29/2019

  Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Genomic Health, Inc. breached their fiduciary duties in connection with the proposed sale of the Company to Exact Sciences Corp..

• Exact Sciences and Genomic Health to Combine, Creating Leading Global Cancer Diagnostics Company

  7/29/2019

  Exact Sciences Corp. and Genomic Health, Inc. announced that the companies have entered into a definitive agreement under which Exact Sciences will combine with Genomic Health for $72.00 per share in a cash and stock transaction valued at $2.8 billion.

• 

  Exact Sciences and Genomic Health Merge to Form Leading Cancer Diagnostics Company

  7/29/2019

  The combined companies will have revenue drivers of two commercially available diagnostics tools, Cologuard and Oncotype DX.
• 

  Certified Great Places to Work By BioSpace Hotbed Regions

  7/18/2019

  Great Place to Work is an organization whose goal it is to assure that all people in the U.S. have a great place to work by 2030. One category for certified companies is Biotechnology & Pharmaceuticals, which listed 36 companies. BioSpace organized these 36 companies into its BioSpace Hotbed Regi...

• Exact Sciences Designated a Great Place to Work-Certified™ Company in 2019

  7/17/2019

  Hundreds of open positions offer opportunity to join growing company

• Exact Sciences to host annual meeting, second-quarter 2019 results webcasts and calls

  7/9/2019

  Exact Sciences Corp. announced that the company will host webcasts and conference calls of its annual stockholders meeting and its second-quarter 2019 financial results.

• Exact Sciences Advances Fight Against Colorectal Cancer With Opening Of New Laboratory

  6/26/2019

  Company's total lab processing capacity expected to reach 7 million by end of year

• Exact Sciences to participate in June investor conferences - May 31, 2019

  5/31/2019

  Exact Sciences Corp. announced that company management will be presenting at the following investor conferences and invited investors to participate by webcast.

• Exact Sciences Advances Pipeline Capabilities with Mayo Clinic

  5/20/2019

  Early data on pancreatic cancer detection presented at Digestive Disease Week® 2019

• Exact Sciences Presents New Data Reinforcing Performance of Cologuard®

  5/17/2019

  Researchers to Present Real-World Findings at Digestive Disease Week® 2019

• Exact Sciences to participate in May investor conferences

  5/1/2019

  Exact Sciences Corp. announced that company management will be presenting at the following investor conferences and invited investors to participate by webcast.

• First-quarter revenue and Cologuard test volume increased 79 percent to $162 million and 334,000, respectively

  4/30/2019

  Estimated Cologuard market share increased to 4.6 percent during the first quarter